This study's aims were: 1) to extract a comprehensive overview of the knowledge, experience and opinions of both community pharmacists and hospital pharmacists regarding biosimilar medicines in France; and 2) to identify the perceived problems and solutions to promoting their prescription. A 2015 web-based survey was conducted by the Observatoire des Medicaments, des Dispositifs Medicaux et de l'Innovation Therapeutique of Alsace. A total of 802 pharmacists responded to the survey. Many (536, 66.8%, [95% confidence interval (CI) 63.6-70.1]) indicated that they were not familiar with biosimilars. Half of community pharmacists (95% CI 42.7-57.3) stated that they were not at all informed about biosimilar drugs, compared with 15.7% (95% CI 12.9-18.6) of hospital pharmacists. Almost all respondents (781, 97.4%,]) had at least one pending question on biosimilars. Most of the questions were related to the manufacturing process, safety, substitution rules and the international non-proprietary name prescription. At the time of the study, 467 pharmacists (58.2%, [95% CI 54.8-61.6]) had already validated a prescription for a biosimilar drug, mainly for filgrastim. These latter were more comfortable in explaining the benefit of biosimilar medicines to the patient. Pharmacists were rather favorable to biosimilar drugs, and about 9 of 10 quoted healthcare cost savings as incentives to their prescription. However, many did not agree with allowing biosimilar substitution. "Patients' wishes to be treated with the originator" and "indication extrapolation" were the two main constraints identified. The survey highlighted the need to provide French pharmacists with accurate and comprehensive information regarding biosimilar medicines.
Introduction
As of May 31, 2014 , 173 biologic medicines were commercialized in France, leading to an expenditure of €5.5 billion/year. Among biotherapies, monoclonal antibodies accounted for the largest budget expense. Of the 10 most expensive drugs in the hospital in 2014 in France, 7 were monoclonal antibodies, namely bevacizumab (Avastin ), infliximab (Remicade ), tras-tuzumab (Herceptin ), rituximab (Mabthera ), eculizumab (Soliris ), cetuximab (Erbitux ) and natalizumab (Tysabri ), and these have incurred an expense of about €1.5 billion. 1 Con-sidering this environment, the availability of biosimilar alterna-tives, i.e., versions of reference biological medicinal products, is critical for containing the health care expenses. [2] [3] [4] [5] [6] [7] [8] [9] A biosimilar of infliximab has been on the European market since the beginning of 2015. Subsequently, the availability of the 6 other monoclonal antibodies listed above, in addition to many other reference biological medicinal products, may encourage the production of similar biological medicinal products when patents expire. 10 Biosimilar drugs are available at more affordable costs. These medicines open up the market to competition and induce price reductions for reference biologi-cal medicinal products. Nevertheless, the market of biosimilars is currently limited and is variable among countries. Many fac-tors may influence the biosimilar market uptake, such as pricing and reimbursement, prescription rules, or incentives imple-mented at a national level. Moreover, originator firms develop a range of strategies to compete with biosimilars. This underlines the need for governments to set up coherent biosimilar pol-icy. [11] [12] [13] [14] [15] [16] In France, some of these frameworks are already in place, such as a reimbursable drug price difference practice (Ecart medicament indemnisable). When hospitals negotiate prices through tender processes for drugs included on the expensive drug list ("liste en sus," a restricted list enabling the complete drug funding in addition to hospitalization stays), the savings, i.e., the difference between the initial price set up by be achieved through pharmacists' confidence in biosimilar the French Economic Committee for Medicinal Products drugs prescriptions. We conducted a literature search of the PubMed/MEDLINE database using the search terms "biosimi-(Comite Economique des Produits de Sante) and the negotiated price is shared equally between the French Social Insurance and lar" and "pharmacist" that yielded only 18 results, including 3 the hospital. Additional initiatives of the French government surveys: 1) a United States (US) survey focusing on biosimilar are also expected to provide strong incentives for physicians to naming conventions; 30 2) a qualitative study investigating the prescribe biosimilar medicines. Similarly to the rules developed barriers to the uptake of biosimilars in Belgium through semifor generics, the upcoming initiatives may encompass targets of structured interviews that included a few pharmacists; 31 and 3) biosimilar prescription for the hospitals, and an additional a 2015 web-based survey investigating the extent of awareness bonus aligned with public health objectives (remuneration sur and understanding of biosimilar products among Japanese objectifs de sante publique) for office-based physicians, but physicians and pharmacists. 32 It therefore appeared essential to these approaches are not in place yet. 17 gather pharmacists' view toward biosimilar medicines. Our Compared to generic medicines, biosimilar drugs are more study aimed first to produce a comprehensive picture of the complex and require extensive investigation to obtain a market-knowledge, experience and opinions of both community and ing authorization, including preclinical, Phase 1 and Phase 3 hospital pharmacists in France toward biosimilar medicines, clinical studies. The regulatory framework applicable to biosi-and second to identify the barriers and potential actions to promilar medicines is well-defined both by European Medicines mote their prescriptions. Agency (EMA) and the Food and Drug Administration. [18] [19] [20] [21] [22] This framework includes some specific concepts, such as the Results indication extrapolation rules enabling the approval of a biosimilar medicine for all the clinical indications of the reference A total of 802 responses to our questionnaire (available as supmedicinal product, solely based on the results of the indication plementary material) were collected. The demographic inforassessed in clinical trials and upon adequate scientific justifica-mation on participating pharmacists is summarized in Table 1 . tion. However, the concept of biosimilarity and related issues Close to 63% of respondents were women (502 pharmacists) about the manufacturing process, extrapolation of indications, and the pharmacists' average age was 42.1 y (standard deviation substitution by the pharmacist, etc., may be questioned by both (SD), § 11.2). Most respondents worked at hospital (616 hospihealth professionals and patients. [23] [24] [25] This is particularly rele-tal pharmacists (76.8%), including 116 pharmacy residents). vant because some of these biosimilar policies are within the Hospital pharmacists were involved in numerous activities remit of the European Union member states and are therefore fi not the same in each country. 26 Indeed, the evaluation of biosi- between na€ıve and pre-treated patients. 29 Nevertheless, the rel-
evant decrees regarding the specific environment required for We asked the pharmacists to indicate whether some statements about biosimilar medicines were accurate or not. A minimum of 59.4% and up to 95.4% of survey respondents gave a correct answer to each of the 9 statements proposed (see Table  2 ). Overall, an average of 7.1 (SD D 1.5) of 9 correct answers were given.
Pharmacists' experience and practices
At the time of the study, 467 of 802 pharmacists (i.e., 58.2%, [95% CI 54.8-61.6]) had already validated a prescription for at least one of the 9 biosimilar drugs available in France, of which 110 (i.e., 23 delivered, mentioned by 9 of 10 pharmacists validating prewhen asking the pharmacists about their remaining questions scriptions for biosimilar drugs. Almost half of the pharmacists related to biosimilar medicines. had already delivered a biosimilar epoetin (Binocrit or Pharmacists were asked whether they agreed to some stateRetacrit ). Only 50 pharmacists had validated prescriptions for ments about biosimilar medicines. Their responses are shown biosimilar infliximab (Inflectra or Remsima ), and 20 for bioin Table 3 . They were rather favorable to the widespread presimilar somatropin (Omnitrope ).
scription of biosimilar drugs. However, slightly more than half Pharmacists were asked if they felt comfortable explaining of them were in favor of the substitution of a reference biologithe benefit of biosimilar medicines to patients, by using a cal medicinal product by its biosimilar product (427 pharmaseven-point scale (from 1 D not at all comfortable, to 7 D cists, i.e., 53.2%, [95% CI 49. 8-56.7] ). This proportion is completely comfortable). They felt less comfortable in explain-relatively small compared with the rate of pharmacists who ing the benefit of biosimilars to patients when they had not agreed with the substitution of a reference chemical medicinal already validated a prescription for a biosimilar drug. 
]).
Pharmacists' opinion "Healthcare cost savings" were identified by close to 92% (95% CI 90.1-93.9) of pharmacists as an incentive to promote the prescription of biosimilar medicines. This was followed by "health policy-makers incentive," "positive impact on patients' access to innovative drugs" and "release of resources allowing treating additional patients," quoted by 72.2% (95% CI 69.1-75.3), 64.8% (95% CI 61.4-68.1) and 62.9% (95% CI 59.6-66.3) of survey respondents, respectively. The "patients' wishes to be treated with biosimilar medicines" was considered as an ele-ment to support the biosimilar drug prescription by 26.1% (95% CI 22.9-29.3) of pharmacists, whereas the opposite sen-tence: "patients' wishes to be treated with the reference biologi-cal medicinal product" was stated by 61.8% (95% CI 58.4-65.2) pharmacists as a barrier to biosimilar prescription. Another item was quoted equally as able to restrain biosimilar prescrip-tion: "extrapolation of efficacy and safety from one therapeutic indication of the biosimilar drug to all indications of the reference biological medicinal product." The issues "lack of information about tolerance" (56.7%, [95% CI 53.2-60.1]) and "risk of increasing patient's worries and concerns" (55.5%, [95% CI 52.0-58.9]) were ranked next in importance, followed by "risk of immunogenicity" (51.6%, [95% CI 48.2-55.1]). Many of these obstacles, e.g., safety issues, were already clearly expressed
Discussion
Our study provided a snapshot of French pharmacists' knowledge, experience and opinion related to biosimilar medicines as of 2015. Very few biosimilar surveys have been conducted, and ours is the first questionnaire survey on the topic performed among pharmacists in a European country. [30] [31] [32] Obviously, pharmacists are not the only key stakeholders in biosimilar market uptake, as biosimilar prescription is closely linked to the physicians' confidence and acceptance. To investigate this matter, we conducted a second web-based survey to give an assessment of knowledge, experience and opinions of hospital-based and officebased French rheumatologists toward biosimi-lar medicines and to identify the barriers and possible options to promote their prescription. 34 The large number of pharmacists who completed our survey combined with their widespread geographical location across the national territory ensured the relevance of the results. We noticed that only a small percentage of the community phar-macists took part in the survey compared with the hospital pharmacists. This difference may be due to a lack of targeted communication, and to the small number of biosimilar drugs now available in community pharmacies. This is further illus-trated by the survey responses, which emphasized that commu-nity pharmacists felt less familiar and raised more questions CI: confidence interval related to biosimilar medicines compared with their hospitalbased counterparts. Nevertheless, it is essential that they take an active role in enhancing biosimilar drugs uptake and patient acceptance. This is even more critical as new biosimilar drugs, such as subcutaneous anti-tumor necrosis factor biosimilars, will be soon available in community pharmacies. For instance, the first etanercept biosimilar (Benepali ) was granted marketing authorization in the European Union in January 2016. With regard to the first section of the questionnaire, it appeared that communication efforts targeting pharmacists could be developed and spread at a national level, specifically by the national health insurance. Its involvement in promoting prescription of generic drugs is still current, but its incentives toward biosimilar medicines appear to have been somewhat limited so far.
When considering the pharmacists' experience related to biosimilar medicines, we found that very few had already delivered biosimilar infliximab. This is linked to the fact that infliximab is restricted to hospital use in France. Also, biosimilar infliximab was launched very recently, and it is therefore likely to be prescribed to a few patients only, especially as ANSM did not recommend switching patients already treated with originator infliximab to a biosimilar medicine until May 2016. 28, 35 Nonetheless, it can already be seen that hospital physicians gradually start prescribing biosimilar infliximab (Inflectra or Remsima ) when looking for information on hospital activity in the PMSI (Program de Medicalisation des Systemes d'Information) national database. 1 We also explored the pharmacists' view on biosimilar drugs. Many were in favor of the implementation of biosimilar medicines. Most also recognized potential cost saving from the use of biosimilar drugs, which could contribute to enhanced access to innovative drugs and to treatment of more patients for a lower price. This topic was already addressed in several studies. [5] [6] [7] [8] In a previous analysis, we showed that management of rheumatoid arthritis patients with biosimilar infliximab in France could result in €13.6 million annual cost savings, enabling treatment of 1,141 additional patients if fully reallocated. 8 Many pharmacists did not feel sufficiently informed about tolerance and iatrogenic effects. However, various clinical trials provided evidence-based information to confirm that there are no meaningful differences in terms of quality, safety and effi-cacy between a reference biological medicinal product and bio-similar drugs. 36, 37 Furthermore, numerous changes in the manufacturing process of originator drugs have occurred since their launch. Drugs that are used now are thus, to some extent, biosimilars of what they were at the time of their introduction on the market. This is the case of originator infliximab (Remicade ), which underwent more than 35 manufacturing process changes since its marketing authorization in 1999. 38 The indication extrapolation concept was also widely questioned and perceived by many pharmacists as a limitation to biosimilar prescriptions. Several studies are performed to provide complementary information, especially in investigating biosimilar use in patients suffering from inflammatory bowel diseases, indications that were not evaluated during clinical development of the biosimilar drug, or in supporting interchangeability of the reference biological drug with its biosimilar equivalent in real-life settings. [39] [40] [41] [42] [43] [44] [45] [46] Biosimilar substitution by the pharmacist was another of the main issues raised in our survey. It is important to note that the biosimilar substitution policy is not the same between Euro-pean countries. 26 For instance, France was one of the first coun-tries to allow for biosimilar substitution, under certain conditions that are stated in the article 47 of the 2014 French Social Security Financing Law. 25, 27 Substitution by the commu-nity pharmacist of a reference biological medicinal product with a biosimilar equivalent belonging to the same biologic group is currently planned for treatment-na€ıve patients. How-ever, there still exist legal uncertainties. For example, specific measures must be taken in order to ascertain the patient always continues treatment with the same medicine. This raises the questions of INN prescription and traceability of the biological drug that has been delivered. This particular topic was addressed by half of the French pharmacists in our survey. Indeed, with limited exceptions, biosimilars share the same INN as their reference biological medicinal products. Auto-matic substitution of one biologic medicine for another can occur in case of prescription by INN, making clear identifica-tion of the biological drugs and pharmacovigilance monitoring more difficult. Concrete solutions are discussed, such as brand-name prescribing rather than INNprescribing. The World Health Organization issued guidelines for naming of biosimi-lars, suggesting biosimilar firms could choose to use a Greek letter suffix added to the INN in order to mention differences in terms of glycosylation of their products. 47, 48 In addition, electronic patient record systems could help track whether a biological treatment was already dispensed and, if so, which one. Moreover, switch studies assessing the effects of interchanging originator infliximab with its biosimilar equivalent are multiplying, providing additional data about its efficacy and tolerance. In light of these reassuring data, an expansion of interchangeability conditions was addressed by the ANSM in May 2016. ANSM now indicates that interchangeability with a biosimilar drug is possible, even when the patient is already being treated with the reference biological medicinal product. 28 These new recommendations are likely to contribute to some amendments in the French Law that may have a great impact on biosimilar market penetration and on the resulting cost savings.
The findings of our investigation have important implica-tions for pharmaceutical practices and for the uptake of biosi-milar drugs. To date, many pharmacists are in favor of the implementation of biosimilar medicines and convinced of their cost savings potential. Moreover, they are at the heart of the concerns raised by potential regulatory changes and their privileged relationship with patients is a valuable asset to promote a clear understanding and to ensure safe use of these particular drugs. Several issues and possible pitfalls related to biosimilars were identified. Pharmacists, in light of their growing experi-ence and provided they are sufficiently informed and involved, will have the opportunity to take a leadership position to sup-port biosimilar medicines prescription.
Materials and methods
A national web-based self-administered survey was conducted by the Observatoire des MEdicaments, des Dispositifs medicaux et de l'Innovation Therapeutique of Alsace, which functions within the regional health agency (Agence Regionale de Sante -ARS). The study was conducted for an 8-weeks period, between June 8 and August 2, 2015.
Development of the survey questionnaire
A self-administered questionnaire (available as supplementary material) was created especially for the purpose of the study, and was validated by a task group constituted of 4 pharmacists, 1 rheumatologist and 1 public health physician and epidemiol-ogist. This questionnaire was composed of 22 questions that were divided into four parts, each one dedicated to the collec-tion of data relative to a specific topic: characteristics of respondents, knowledge, experience and opinion with regard to biosimilar medicines, respectively. The main part of the online questionnaire was composed of closedended questions since these were more convenient for pharmacists to answer, required less coding and were easier to analyze. A last open-ended question allowed us to gather the pharmacists' com-ments on the topic.
Pilot study
A pilot study was conducted to check for comprehension of the questionnaire, verify its accuracy and completeness with regard to the research topic, identify possible redundancy among the 22 questions, and ensure ergonomics of the data-collecting method.
Target population
Invitations to participate to the web-survey were sent out by email to almost 3000 hospital pharmacists and to more than 6500 community pharmacies with the help of the regional pharmacists' association (Conseil Regional de l'Ordre des Phar-maciens) of 11 of 27 regions of France (22 regions in mainland France and its 5 overseas dependencies) at the time of the sur-vey. Pharmacy residents were also targeted with the help of the National Federation of pharmacy residents trade unions or associations FNSIP-BM (Federation Nationale des Syndicats d'Internes en Pharmacie et Biologie Medicale) and pharmacy resident associations.
Statistical analysis
Major changes to the questionnaire were made following the pilot study; thus, questionnaires of the pilot study were not combined with the main study for analysis. Data were gathered and analyzed using Microsoft Excel 2007. Descriptive statis-tics were reported by numbers, averages and standard devia-tions, proportions and 95% confidence intervals. Pearson's Chi-squared tests (x 2 tests) and Student ttests were performed using R, version 3.1.0. A p-value below 0.05 was considered to be of statistical significance.
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